GFH-375

Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.

Verastem Oncology secured a new credit facility of up to $150 million and a $7.5 million equity investment with Oberland Capital, refinancing existing debt with Oxford Finance.

The FDA approved Opdivo Qvantig, a subcutaneous injection of nivolumab, for adult solid tumors previously approved for intravenous Opdivo.

Verastem Oncology anticipates a potential FDA decision on avutometinib plus defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) by June 30, 2025.

The FDA has accepted Verastem Oncology's NDA for avutometinib plus defactinib with Priority Review for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).